A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)

Trial Profile

A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Gimatecan (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 According to a Leadiant Biosciences media release, this trial was originally conducted by Sigma-Tau Pharmaceuticals, Inc. but later on this company's name changed to Leadiant Biosciences
    • 26 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top